Endocrine Abstracts

Goal of research: To evaluate the clinical efficacy of phosphocreatine in the combined metabolic therapy of diabetic neuropathy at an early stage.

Materials and methods: A pilot study was carried out with participation of 36 patients suffering from DM 2. Using the method of randomization the patients were divided into two groups. Apart from the standard therapy the main group (n=24) received phosphocreatine (intravenous infusion dose 2 g per 100.0 of saline solution). DN was evaluated using the Neuropathic Symptomatic Score (NSS) by means of filling in a questionnaire used for analysis of the presence and strength of neuropathic symptoms. As well as using the Neuropathic Dysfunctional Account (NDA), at that vibration, tactile, temperature, pain sensitivities of lower limbs. The main parameters of efficacy were NSS score after 6 weeks of treatment and NDA score after 6 weeks of therapy.

Results, discussion: A faster clinical effect was noted in the main group during analysis of the score, relief of neuropathic symptoms occurred even without changes in the metabolic control. Apart from the slow-down of neuropathic symptoms some patients from the main group demonstrated growth of hair on legs (12.5%) which was considered as a positive potentiating effect of phosphocreatine on the background therapy of diabetic neuropathy.

Conclusions: 1. The ITT-analysis in the primary end point after the combined therapy with application of phosphocreatine showed the decrease of NSS score by 42.1%, and NDA score by 13.3%.

2. Use of phosphocreatine as a cytoprotective agent in the combined DN therapy is pathogenetically substantiated and allows to expand the opportunities of drug therapy for patients suffering from DN.

3. Results of the conducted trials demonstrate a potential for further study of administration of this medicine in a larger long-term randomized and controlled trial.